NIH alone awards roughly $6B annually to Cancer related R&D grants and contracts. The scope of funding support covers much of the R&D cycle, from basic research, through pre-clinical activities and early phase clinical trials.
In this webinar, we discuss key cancer related opportunities, focusing on the new set of solicitations from the National Cancer Institute (NCI) and the soon to be released CDMRPs (DoD) that are available for life science organizations.
In a world in which both medical diagnostics and therapies are shifting towards minimally invasive technologies, it is not surprising that steadily increasing non-dilutive funding is available for innovative medical device companies.
The scope of funding support covers the entire R&D cycle, from early stage exploratory and discovery work all the way to late stage clinical research and validation.
In this webinar, FreeMind experts discuss the latest trends at the NIH and the funding opportunities available with respect to medical devices.
Non-US applicants are eligible for the majority of the non-dilutive pockets of money including NIH, Department of Defense, BARDA etc. Currently, the National Institutes of Health (NIH) are actively funding over 1000 projects in the excess of $1.3B, taking place outside the US and awarded to non-US applicant organizations. And, when taking into account collaborations and partnerships between domestic and foreign entities, the funded R&D dollars outside the US even exceed the above.
In this presentation, we provide insight into the non-dilutive funding landscape with an emphasis on the NIH, Department of Defense and other government agencies. FreeMind experts will describe the various pockets of money available for non-US applicants, potential for funding, and means to maximize chances for award.
Within the non-dilutive funding space one can find pockets of money in the billions of dollars directed at unmet medical needs related to CNS/PNS ailments. The scope of funding support covers much of the R&D cycle from proof of concept to late stage clinical.
In this webinar, we discuss key CNS/PNS related funding opportunities, with an emphasis on NINDS, NIA, and NIMH.
In order to maximize your funding potential, all sources of funding must be considered, including the less traditional ones.
The NIH’s R21 mechanism aims to fund very early stage proof of concept type programs of up to 2 years at about $300,000, whereas the R01 mechanism is more suitable for longer programs of up to 5 years, totaling close to $3,000,000. Other agencies such as the Department of Defense, BARDA, FDA, and NSF also have awards for research in the life sciences.
In this webinar, we share insight into alternatives to the classic SBIR/STTR mechanisms. We will discuss methodology for establishing both responsiveness as well as competitiveness and how to increase chances for award.
SBIR/STTR awards account for over $780,000,000 awarded per year by NIH alone. These are excellent sources of funding aimed at promoting R&D activities of US-based small businesses as well as collaborations with Academics.
SBIR/STTRs differ from traditional NIH mechanisms in that they are highly product driven and ultimately are seeking commercialization of novel therapies, diagnostics, devices, etc.
In this webinar, we discuss process for applying, guidelines, key success components and insight into increasing chances for award.
Every year, US-based non-dilutive sources of funding award billions of dollars towards clinical stage research in the Life Sciences.
Funding is available for clinical stage funding across scientific fields including Infectious Diseases, Neurosciences, Cardiovascular, and many more. These funds come from multiple Institutes within the NIH, such as NIAID, NIAMS, NIDDK, from BARDA, and from the DOD.
In this webinar, we discuss the process for applying, guidelines, key success components and insight into increasing chances for award.
Every year, US-based non-dilutive sources of funding award billions of dollars towards pre-clinical stage research in the Life Sciences.
Funding is available for pre-clinical research across scientific fields including Infectious Diseases, Oncology, Neurosciences, and many more. These funds come from Institutes within the NIH, such as NIAID, NCI, NINDS, the NSF, the DoD, and private foundations. The NIH alone annually funds over $15B to pre-clinical stage R&D in the life sciences.
In this webinar we discuss the process for applying, guidelines, key success components, and insight into increasing chances for award.
NIH alone awards roughly $6B annually to Cancer related R&D grants and contracts. The scope of funding support covers much of the R&D cycle with an emphasis on pre-clinical work, and may cover clinical stage activities as well.
In this webinar, we discuss key cancer related opportunities, mainly within the National Cancer Institute (NCI), that are available for life science organizations.
The National Institute of Allergies and Infectious Diseases (NIAID) awards close to $6,000,000,000 annually. Taking into account activities by DTRA, DARPA, US Army, BARDA, etc., this is a funding force no one in the field can afford to ignore.
In this webinar, we introduce you to Biodefense and Infectious Diseases sources of funding such as NIAID, DTRA, DARPA, US Army, and BARDA, and give examples of current open solicitations. We discuss the process for applying, major challenges, and how to maximize your chances for award.
FreeMind Group
6 Liberty Square #2783
Boston, MA 02109
We use cookies to gather web statistics that help us improve our site. We store no personal details.
OKLearn moreWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy